

**Malignant lymphomas.**  
Modern classification and management of the most frequent entities

**LEARNING OBJECTIVES**

- 1.- To highlight the pathological bases of the most recent lymphoma classification
- 2.- To understand the role of PET in staging, re-staging and follow-up
- 3.- To review the treatment strategy for the most common lymphoma types
- 4.- To dissect the peculiarities of lymphomas arising in particular extranodal sites
- 5.- To illustrate special and innovative treatment strategies
- 6.- To discuss clinical cases between faculty and participants

**CHAIR**

Chair: Michele Ghielmini, CH

**FACULTY**

Wolfram Brugger, DE  
Elias Campo, ES  
Michele Ghielmini, CH  
Steven Le Gouill, FR  
Leticia Quintanilla-Fend, DE  
Martin Hutchings, DK  
Lena Specht, DK  
Emanuele Zucca, CH

**Friday, 27 November 2015**

08:45-09:00 15'	<b>Opening and Welcome</b>	
15'	Welcome from ESMO, objectives and scientific introduction	
09:00-10:30	<b>Session 1 Pathology and staging</b>	<b>Chairs:</b>
30'	The history of lymphoma classification and the WHO 2008	Elias Campo, ES
20'	Methods used to diagnose lymphoma	Leticia Quintanilla-Fend, DE
20'	Epidemiology of lymphomas	Michele Ghielmini, CH
20'	Role of PET in staging and treatment of lymphomas	Lena Specht, DK
10:30-11:00	Break	
11:00-12:30	<b>Session 2 Indolent</b>	<b>Chairs:</b>
20'	Pathology of the indolent lymphoid neoplasms	Elias Campo, ES
20'	Treatment of follicular lymphoma	Michele Ghielmini, CH
20'	Treatment of chronic lymphocytic leukemia	Wolfram Brugger, DE
2x15'	2 x Clinical cases from participants	All faculty

Each 15 min slot for clinical cases comprises 7' case presentation plus 8' Q&A/ panel discussion

12:30-13:00	Session 3 Q&A Session	All faculty
-------------	--------------------------	-------------

12:30-13:30	Lunch	
-------------	-------	--

14:00-15:30	Session 4 Aggressive	Chairs:
20'	Pathology of aggressive lymphomas	Leticia Quintanilla-Fend, DE
30'	Treatment of DLBCL	Martin Hutchings, DK
20'	Lymphoma in HIV+ patients	Wolfram Brugger, DE
20'	Other aggressive lymphomas	Michele Ghielmini, CH

15:30 – 16:00	Break	
---------------	-------	--

16:00-17:30	Session 5 Mantle cell and Extranodal	Chairs:
30'	Management of mantle cell lymphoma	Steven Le Gouill, FR
20'	CNS lymphoma	Lena Specht, DK
20'	GI tract lymphoma	Emanuele Zucca, CH
20'	Waldenstroem/splenic marginal zone lymphoma	Wolfram Brugger, DE

17:30-18:00	Session 6 Q&A Session	All faculty
-------------	--------------------------	-------------

19:30-22:30	Dinner	
-------------	--------	--

## Saturday, 28 November 2015

08:30-10:30	Session 7 Hodgkin	Chairs:
20'	Treatment of early stage	Martin Hutchings, DK
20'	Treatment of advanced stage	Emanuele Zucca, CH
20'	Prevention and screening of long term side effects	Lena Specht, DK
2x15'	2 x Clinical cases from participants	All faculty

Each 15 min slot for clinical cases comprises 7' case presentation plus 8' Q&A/ panel discussion

10:00 – 10:30	Coffee break	
---------------	--------------	--

10:30-12:00	Session 8 T-cell lymphomas and special treatments	Chairs:
20'	Systemic T-cell lymphomas	Martin Hutchings, DK
30'	New drugs for lymphoma	Emanuele Zucca, CH
10'	Autologous and allogeneic transplantation	Steven Le Gouill, FR
2x15'	2 x Clinical cases from participants:	All Faculty

Each 15 min slot for clinical cases comprises 7' case presentation plus 8' Q&A/ panel discussion

12:00-12:30	Session 9 Closing remarks and Q&A Session	All faculty
-------------	--	-------------

12:30-13:15	Lunch and departure	
-------------	---------------------	--